The British Society for Haematology has just released (November and December 2023) new guidelines for myelofibrosis.

As these are British guidelines, not all treatment options are available in Australia and Australian practices may vary.
However the guidelines provide useful insight into diagnosis and prognosis considerations as well as the growing array of treatment options becoming available for myelofibrosis patients.

There are two parts to the guidelines:

• Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline;

• The management of myelofibrosis: A British Society for Haematology Guideline (a companion guideline)

The management guideline includes detailed advice on specific situations such as:

• Management of myelofibrosis-associated anaemia
• Management of thrombocytopenic patients
• Role of splenectomy in myelofibrosis
• Myelofibrosis in paediatric, teenage and young adult population
• Myelofibrosis and pregnancy
• Allogeneic stem cell transplantation for myelofibrosis